Xeris Biopharma Holdings, Inc. (XERS) Cash Flow Statement

The OCF/NI ratio of -0.58 in 2026Q2 underscores that reported losses are not cash-consuming, with SBC of $15.2M and D&A of $6.4M bridging the gap. This suggests that operational cash generation is stronger than net income indicates, but investors should monitor the sustainability of these non-cash adjustments.

The trajectory shows a clear inflection: after four consecutive quarters of negative FCF through 2025Q1, the last five quarters have been positive, culminating in a 19.1% margin. This improvement appears driven by revenue scaling and working capital releases, though the 2026Q2 margin dipped from 23.0% in 2025Q4, warranting monitoring for sustainability.

With CapEx/Revenue consistently below 1%, Xeris's capital requirements are minimal, allowing nearly all operating cash flow to convert to FCF. This suggests that growth is not constrained by heavy fixed-asset investment, but investors should consider whether this underinvestment could limit future capacity.

The erratic WC changes, including a -$7.2M drag in 2026Q2, suggest that collections and payables are not yet stable. This volatility may reflect channel dynamics or inventory management, and investors should monitor whether these swings normalize as revenue scales.

The company has been aggressively repurchasing shares, with cumulative buybacks of $48.5M over the last five quarters, despite only recently achieving positive FCF. This deployment strategy may signal management's confidence, but it also reduces cash reserves that could be used for other purposes, and the sustainability of this pace depends on continued cash generation.

The $108.3M gap between cumulative OCF and net income highlights that reported losses are largely non-cash, driven by SBC and D&A. This divergence suggests that the company's cash-generating ability is stronger than GAAP earnings imply, but investors should be cautious as SBC dilution may offset shareholder value.